Clinical Trials | January 15, 2026
Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Full approval will depend on verification of clinical benefit in a confirmatory trial
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Subscribe To Our Newsletter & Stay Updated
